In addition, although the use of PD-L1 IHC assays for predicting anti-PD-1/PD-L1 immunotherapy response was approved in some cancers [e.g., pembrolizumab in non-small cell lung cancer (35)], most cancers showed inconsistencies between PD-L1 immunohistochemistry readout and response (36). This evidence concerns the gene CD274 and non-small cell lung carcinoma.